This inventor holds 5 USPTO granted patents and 9 published patent applications and 1 EPO patent. Top assignees: The University of Tokyo, Complecure, Inc., Microbial Chemistry Research Foundation. Active years: 2010-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Bunkyo-ku, JP (2010)
- Tokyo, JP (2015 - 2024)
Company Filing History:

Years Active: 2010-2026
Title: Kenzo Yamatsugu: Innovator in Bioconjugate Chemistry
Introduction
Kenzo Yamatsugu is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of bioconjugate chemistry, particularly in the development of innovative compounds for therapeutic applications. With a total of 5 patents to his name, Yamatsugu continues to push the boundaries of scientific research.
Latest Patents
One of his latest patents is the "Conjugate of biotin-modified dimer and phthalocyanine dye." This invention aims to provide a conjugate that is utilized in photoimmunotherapy, enhancing the effectiveness of cancer treatments. Another notable patent is the "Artificial catalyst system for selective acylation of chromosome protein." This system allows for the selective acylation of chromosome proteins, achieved through a combination of an acyl CoA activating catalyst and acyl CoA or its derivatives.
Career Highlights
Throughout his career, Kenzo Yamatsugu has worked with esteemed institutions, including the University of Tokyo and Savid Therapeutics Inc. His work has been instrumental in advancing the understanding and application of bioconjugates in medical science.
Collaborations
Yamatsugu has collaborated with notable scientists such as Motomu Kanai and Masakatsu Shibasaki. These partnerships have fostered innovation and contributed to the success of his research endeavors.
Conclusion
Kenzo Yamatsugu is a distinguished inventor whose work in bioconjugate chemistry has the potential to revolutionize therapeutic approaches. His patents reflect a commitment to advancing science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile